tbuckley/cabot-search huggingface dataset:
Congress Approves Increase in Cancer Funding
Journal: Cancer Discovery (2021)

Abstract The federal spending bill enacted by the U.S. Congress in December for fiscal year 2021 totals $1.4 trillion, plus another $900 billion in emergency COVID-19 relief funding. The $1.4 trillion includes budget increases for the NIH, NCI, and FDA that help the agencies keep pace with inflation. Research advocates say more than $10 billion in emergency supplemental funds for the NIH is urgently needed to support medical research affected by the COVID-19 pandemic.
Gold coating of coronary stents increases neointimal proliferation following stent implantation: A prospective randomized multicenter trial with quantitative intravascular ultrasound at 6 months Juergen vom Dahl, Phillip K. Haager, Eberhard Grube, Michael Gross, Eckhard P. Kromer, Christian W. Hamm, Rainer Hoffmann, Thorsten Reinecke, Heinrich G. Klues. Medizinische Klinik I, University Hospital Aachen, Aachen, Germany
Journal: Journal of the American College of Cardiology (2001)
LAW AND MEDICINE
Authors: Richard P. Bergen
Journal: JAMA (1968)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
index to advertisers
Journal: JAMA (1967)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Error in Funding/Support
Journal: JAMA Network Open (2021)

Lap Ah Tse, PhD; Chuangshi Wang, PhD; Sumathy Rangarajan, MSc; Zhiguang Liu, PhD; Koon Teo, MBBCh, PhD; Afzalhussein Yusufali, MD; Álvaro Avezum, PhD; Andreas Wielgosz, PhD; Annika Rosengren, PhD; Iolanthé M. Kruger, PhD; Jephat Chifamba, DPhil; K. Burcu Tumerdem Calik, MD; Karen Yeates, MD; Katarzyna Zatońska, PhD; Khalid F. AlHabib, MBBS; Khalid Yusoff, MBBS; Manmeet Kaur, PhD; Noorhassim Ismail, MD; Pamela Seron, PhD; Patricio Lopez-Jaramillo, PhD; Paul Poirier, PhD; Rajeev Gupta, PhD; Rasha Khatib, PhD; Roya Kelishadi, MD; Scott A. Lear, PhD; Tarzia Choudhury, MA; Viswanathan Mohan, DSc; Wei Li, PhD; Salim Yusuf, MD
Patient-reported outcomes (PROs) in pancreatic cancer clinical trials (CTs).
Authors: Udhayvir Singh Grewal, Danya Ahmed, Lovekirat Singh Dhaliwal, Daniel A. Laheru, Emil Lou, Muhammad Shaalan Beg, Ryan David Nipp, Arjun Gupta
Journal: Journal of Clinical Oncology (2022)

534 Background: Incorporating PROs into CTs is critical for patients with pancreatic cancer, as these individuals often experience a high symptom burden and prioritize maximizing quality of life (QOL). Methods: We reviewed protocols of completed U.S. CTs listed on ClinicalTrials.gov that investigated curative/palliative interventions in pancreatic cancer from 1995-2020. We assessed up to August 2021 if CT publications reported PRO results through linked publications and an independent search through PubMed/MEDLINE. We extracted CT details (funding, eligibility, etc), and if PROs (outcome directly reported by patients) were listed as an endpoint (primary/secondary/exploratory). We classified interventions as cancer-directed (e.g. chemotherapy), supportive care (e.g. neurolysis), or other (e.g. curcumin). Results: We reviewed 619 protocols and included 379 in the analysis. Most CTs investigated cancer-directed interventions (317, 83.6%). Only 43 (11.4%) included PROs as endpoints (Table). In these, most of the PROs assessed QOL (34, 79.1%) and pain (15, 34.9%). For the 33/43 (76.7%) protocols that listed a specific PRO instrument, EORTC-QLQ C30 (11/33, 33.3%) was the most common. Only 6 (18.2%) protocols included pancreatic cancer-specific PROs, such as QLQ-PAN26. Supportive care CTs were more likely to assess PROs than cancer-directed CTs (odds ratio, OR= 62.6, 95% CI 16.7-234.3, p&lt;0.0001). Protocols listed PROs as a primary, secondary, and exploratory endpoint in 15 (34.9%), 25 (58.1%), and 3 (6.9%) CTs respectively. Most CTs (13/15, 86.7%) with PROs as a primary endpoint evaluated supportive care interventions. Of 15 CTs with PROs as a primary endpoint, 10 (66.7%) had results published. Of 28 CTs assessing PROs as a secondary/exploratory outcome, 20 (71.4%) had published results and 12 (42.9%) included PRO data. Conclusions: From 1995-2020, only 11.4% of pancreatic cancer CTs incorporated PROs as endpoints. Supportive care CTs were more likely to include PROs than cancer-directed CTs. Our findings underscore the need to improve efforts to incorporate PROs into CTs for patients with pancreatic cancer. Data as number (%).[Table: see text]
Recent opinions of the Council on Ethical and Judicial Affairs
Journal: JAMA (1986)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Decreased IL-6 concentrations as a marker of successful treatment in patients with chronic heart failure Bjoern Mayer, Stephan R. Holmer, Christian Hengstenberg, Guenter A. J. Riegger, Heribert Schunkert. University of Regensburg, Klinik Innere Med. II, Regensburg, Germany
Journal: Journal of the American College of Cardiology (2001)
Erratum
Journal: BMJ (1898)

CHANGING TH.E DOCTQR."INQUIBENS.-Theincident related by our correspondent is a good illustra- tion of the necessity for medical men to communicate with each other when patients are intending to change from one to the other.Dr. C. acted quite consistently with ethics in attending for Dr. B., stating his position to the patient, and declining further attendance.It would have beeni well to have sent a line to Dr. B., saying what he had done.When the patient again sent for Dr. C. he should have declined attending until he was satisfied that Dr. B. had been communicated with and had acquiesced.The difference in the statements of the doctor,and the-patient more forcibly still-, pQints to. the desirability of doctors not acting until some mutual explanat4ong have taken place.
Progress in Development of Immunization Registries—United States, 2000
Journal: JAMA (2001)

EMERGENCY DEPARTMENT (ED) STAFF caring for patients contaminated with toxic chemicals are at risk for developing toxicity from secondary contamination.This report describes three cases of occupational illnesses associated with organophosphate toxicity caused by exposure to a contaminated patient and underscores the importance of using personal protection equipment (PPE) and establishing and following decontamination procedures in EDs and other areas of acute care hospitals.
Lack of association between polymorphisms in four candidate genes and myocardial infarction Christian Hengstenberg, Stephan R. Holmer, Bjoern Mayer, Susanne Engel, Hannelore Loewel, Guenter A. J. Riegger, Heribert Schunkert. University of Regensberg, Cardiology, Regensburg, Germany
Journal: Journal of the American College of Cardiology (2001)
MUCOUS OR MEMBRANOUS URETERITIS.
Journal: JAMA (1901)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Methylprednisolone coated stents decrease neointimal hyperplasia in a porcine coronary model Qiang Bei Ping, Huang Yanming, Lan Wang, Ineke Vermeire, Eric Verbeken, Etienne Schacht, Ivan K. De Scheerder. UH GASTHUISBERG KUL, LEUVEN, Belgium
Journal: Journal of the American College of Cardiology (2001)
Coagulation Factor V Mediates Inhibition of Tissue Factor Signaling By Activated Protein C
Authors: Hartmut Weiler, Hai-Po Liang, Edward J Kerschen, Alireza Rezaie, Jose A. Fernandez, Rodney M. Camire, Wolfram Ruf, John H. Griffin, Raffaele Toso
Journal: Blood (2015)
Endoscopic sinus surgery with medical therapy versus medical therapy for chronic rhinosinusitis with nasal polyps: a multicentre, randomised, controlled trial
Authors: Evelijn S Lourijsen, Sietze Reitsma, Marleen Vleming, Gerjon Hannink, Gwijde F J P M Adriaensen, Marjolein E Cornet, D Rienk Hoven, Ward J M Videler, Jochen H Bretschneider, Susanne M Reinartz, Maroeska M Rovers, Wytske J Fokkens
Journal: The Lancet Respiratory Medicine (2022)
The special care of human milk.
Journal: BMJ (1978)

The special care of human milk Recent publications on human milk have emphasised how far its unique biochemical composition sets it apart from even the most modern humanised milk formulas.For example, Lonnerdal et all have drawn attention to the high concentra- tion of free amino-acids in human milk, in which they make up to a fifth of the total milk nitrogen compared with 5%. in cows' milk and most milk formulas.Furthermore, among the amino-acids in human milk free taurine is prominent2 in contrast to its low concentration in cows' milk and its virtual absence from formula feeds.Apparently babies cannot synthesise taurine from cysteine-a matter of theoretical concern in view of the high concentration of taurine found in the developing central nervous system of the newborn of many species, including man.Our understanding of the antimicrobial properties of human milk has also grown recently.Lactoferrin, for example, has been shown to serve the dual purpose of an iron-transport protein and a bacteriostatic agent for Escherichia coli.3Milk IgA provides the baby with a wide range of specific immunity, reflecting the bacterial flora of the individual mother and her child.4The specific function of the many lymphocytes and macrophages in human milk is currently under active investigation in the wake of a report from Pitt, Barlow, and Heird,5 which showed that in newborn rats the cellular component of the species-specific milk could protect against experimentally induced necrotising enterocolitis-a condition of growing importance which is causing major concern in special care baby units throughout the world.6Research studies of the characteristics of human milk have, then, led to a reappraisal of the feeding of low-birthweight and preterm infants.Human milk has come back into favour in special care nurseries and there has been a resurgence of interest in human milk banks.Such banks were established in Britain and the United States before the second world war and detailed standards for the operation of mothers' milk bureaux were published by the American Academy of Pediatrics in 1943.7After a period of growth in the postwar years8 human milk banks went into a decline with the develop- ment of improved dried milk formulas.Nevertheless, there were still five commercial milk banks operative in Britain in 1975.9The procedures, however, used in the past to secure the sterility of banked milk-boiling or pasteurisation followed by terminal autoclaving-must have killed the milk cells and denatured the proteins, thus destroying many of the factors that make human milk desirable for preterm and lowbirthweight infants.
Predictors of long-term survival among patients with brain metastases
Authors: Nayan Lamba, Paul J Catalano, Wenya Linda Bi, Patrick Y Wen, Daphne A Haas-Kogan, Daniel N Cagney, Ayal A Aizer
Journal: Neuro-Oncology (2021)

Brain metastases (BrM) are common among patients with solid malignancies.1 The prognosis of patients with BrM has generally been poor, with population-based studies demonstrating survival times of ≤12 months for patients with BrM at cancer diagnosis and ≤4 months for most elderly patients (>65 years), irrespective of primary site.2,3 However, longer-term survival is increasingly observed among select subsets, largely due to advances in systemic and local, brain-directed treatment.4,5 Here, we characterize factors associated with long-term (≥5 years) survival among a contemporary cohort of patients with brain metastases. We identified 1281 patients diagnosed with BrM without leptomeningeal disease at Dana-Farber/Brigham and Women’s Cancer Center between January 2008 and December 2015 (most recent date to permit 5-year survival analyses) who either died or survived ≥5 years. Median survival and 5-year survival estimates were calculated with the Kaplan-Meier method. Multivariable logistic regression was used to characterize predictors of 5-year survival after BrM diagnosis. Patients censored (ie, lost to follow-up) before 5 years were excluded from the multivariable logistic regression model (N = 51), leaving 1230 patients to be analyzed.
Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: Prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction A. Mark Richards, Robert Doughty, M. Gary Nicholls, Stephen MacMahon, Norman Sharpe, Judy Murphy, Eric A. Espiner, Christopher Frampton, Tim G. Yandle. Christchurch School of Medicine, Christchurch, New Zealand, University of Auckland, Auckland, New Zealand
Journal: Journal of the American College of Cardiology (2001)
Neonatal inflammatory skin and bowel disease type 1 caused by a complex genetic defect and responsive to combined anti‐tumour necrosis factor‐α and interleukin‐12/23 blockade
Authors: Liat Samuelov, Ofer Sarig, Kiril Malovitski, Shir Bergson, Odile Meijers, Dror S. Shouval, Eli Sprecher
Journal: British Journal of Dermatology (2022)

ADAM17, encoding ADAM metallopeptidase domain 17, is a membrane-bound shedding protease, which plays an essential role during normal development and in the regulation of inflammation. Biallelic variants in ADAM17, resulting in complete loss of ADAM17 expression, have been reported in individuals affected by rare neonatal inflammatory skin and bowel disease 1 (NISBD1). Here, we report on a young female individual with NISBD1 featuring erythroderma, atrichia, nail dystrophy, oesophageal strictures, intractable diarrhoea, profound failure to thrive and recurrent cutaneous and systemic infections. In this case, NISBD1 was found to result from a complex compound heterozygous defect consisting of a large genomic deletion spanning exons 6 and 7 in addition to a splice site variant causing exon 17 skipping. Skin manifestations dramatically improved in response to combined anti-tumour necrosis factor-α and interleukin-12/23 blockade, while gastrointestinal symptoms were controlled with budesonide. Our study further expands the phenotypic and genetic spectrum of NISBD1 and suggests that combined immunosuppressive treatments may be indicated in this complex condition. What is already known about this topic? Biallelic loss-of-function variants in ADAM17, encoding ADAM metallopeptidase domain 17, have to date been reported in only four families with neonatal inflammatory skin and bowel disease 1 (NISBD1). NISBD1 features variable disease phenotypes associated with different degrees of severity. What does this study add? We report a case of a patient with NISBD1 caused by a unique genetic defect consisting of a combination of a splice site variant leading to exon 17 skipping and a large deletion spanning exons 6-7 of the ADAM17 gene. The severe cutaneous phenotype in our patient responded to a combination of ustekinumab and certolizumab.
Race, sex, age, and geographic disparities in pancreatic cancer incidence.
Authors: Natalie Moshayedi, Anna Loraine Escobedo, Shant Thomassian, Arsen Osipov, Andrew Eugene Hendifar
Journal: Journal of Clinical Oncology (2022)

520 Background: Pancreatic cancer has a poor prognosis and a 5-year survival rate of 10%. A population-risk level analysis of pancreatic cancer will identify epidemiologic risk factors including geographic, racial, ethnic, and sex inequities which could lead to improved prevention strategies. Methods: Incidence data for invasive pancreatic cancer from 2009 through 2018 was obtained from the Surveillance, Epidemiology, and End Results Research (SEER) Plus Limited-Field database (SEER 21) that covers about 37% of the US population. Age-adjusted incidence rates (AAIR) and trends were estimated by race, sex, age categories (ten-year age groups starting from age 30), and county-level rural-urban classification developed by the United States Department of Agriculture (USDA). Trends over the period are described using the annual percent change (APC) calculated using weighted least squares method. Results: Overall pancreatic cancer incidence (per 100,000 population) for all ages during 2009-2018 was 13.0. Rates were highest among Black (15.4), followed by non-Hispanic white (13.2) and Hispanic (11.6) groups in both men and women. Males carries a higher rate of incidence (14.8) than females (11.6) in pancreatic cancer although both sexes experienced a 0.6% increase in incidence yearly. Incidence of pancreatic cancer increased with age across all ethnicities in men and women. The highest rate of incidence was found in ages 80 and above (99.5) and the lowest in age group 30-39 (1.0). Pancreatic cancer rates increased by 0.6% yearly and increased in every racial/ethnic group for both males and females, except Black males (0.0) and American Indian/Alaska Native females (-0.2). Although incidence in urban counties (13.1, n = 321) and rural counties (12.8, n = 411) was comparable, rural countries observed a faster increase in rates between 2009 and 2018 (p &lt; 0.05). Conclusions: Incidence of pancreatic cancer has increased from 2009 to 2018 across all ethnicities and in both men and women. Minorities, males, and individuals living in rural counties are disproportionately affected by pancreatic cancer. Additionally, older individuals have a higher incidence of pancreatic cancer, suggesting an increased risk in this patient population. This data will inform strategies to identify high-risk populations and implement preventative care, screening, and surveillance.[Table: see text]
Error in Table 4
Authors: Ezra Golberstein
Journal: JAMA Pediatrics (2020)

Barbara J. Stoll, MD; Karen M. Puopolo, MD, PhD; Nellie I. Hansen, MPH; Pablo J. Sánchez, MD; Edward F. Bell, MD; Waldemar A. Carlo, MD; C. Michael Cotten, MD, MHS; Carl T. D’Angio, MD; S. Nadya J. Kazzi, MD, MPH; Brenda B. Poindexter, MD, MS; Krisa P. Van Meurs, MD; Ellen C. Hale, RN, BS, CCRC; Monica V. Collins, RN, BSN, MaEd; Abhik Das, PhD; Carol J. Baker, MD; Myra H. Wyckoff, MD; Bradley A. Yoder, MD; Kristi L. Watterberg, MD; Michele C. Walsh, MD, MS; Uday Devaskar, MD; Abbot R. Laptook, MD; Gregory M. Sokol, MD; Stephanie J. Schrag, DPhil; Rosemary D. Higgins, MD; Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network
Inflammation plays a more important role in coronary atherosclerosis in patients with low cholesterol level Bon Kwon Koo, Donghoon Choi, Hee Doo Kyung, Yangsoo Jang, Won-Heum Shim, Seung-Yun Cho. Yonsei Cardiovascular Center and Cardiovascular Research Institute, Seoul, South Korea
Journal: Journal of the American College of Cardiology (2001)
COVID‐19 确诊患者的五种常见皮肤表现
Journal: British Journal of Dermatology (2020)

COVID‐19 又称冠状病毒,是由 SARS‐CoV‐2 引起的一种传染病。2019 年 12 月首次发现,2020 年 3 月,世界卫生组织宣布 COVID‐19 已成为一种全球大流行病,可能影响不同的器官系统,而且早期报告显示有皮肤症状。研究人员与西班牙皮肤科医生合作,审查了 375 名疑似或确诊 COVID‐19 的患者,目的是通过相应的影像对与 COVID‐19 相关的不同类型皮肤症状进行详细分类。